Ovarian cancer is one of the major health- and life-threatening diseases among females. In recent years

poly (ADP-ribose) polymerase inhibitors (PARPi)

as novel molecular-targeted therapy agents that bring benefits to ovarian cancer patients

have been recommended as maintenance therapy for platinum-sensitive recurrent ovarian cancer patients and postoperative maintenance therapy by several clinical guidelines. However

the safety issues

especially the hematological toxicities of the drugs

should be carefully regarded. This review compared the pharmacological characteristics and hematological toxicities of three different PARPi

so as to provide more information of the clinical application for the recurrent ovarian cancer patients.